Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares traded up 5.7% during mid-day trading on Thursday . The company traded as high as $3.75 and last traded at $3.70. 689,378 shares traded hands during trading, an increase of 20% from the average session volume of 573,481 shares. The stock had previously closed at $3.50.
A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Maxim Group set a $14.00 price objective on Adamis Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 5th. B. Riley set a $10.00 price objective on Adamis Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 30th. Finally, ValuEngine downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $10.33.
The company has a debt-to-equity ratio of 0.06, a current ratio of 3.93 and a quick ratio of 3.79. The stock has a market capitalization of $121.03, a price-to-earnings ratio of -5.29 and a beta of 0.19.
TRADEMARK VIOLATION NOTICE: “Adamis Pharmaceuticals (ADMP) Trading 5.7% Higher” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/08/adamis-pharmaceuticals-admp-trading-5-7-higher.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.